[Aztreonam--new antibiotic for treating infections caused by gram-negative aerobic bacteria].
Aztreonam is the first synthetic monobactam used in practical medicine. It is effective in Gram-negative aerobe infections. It inhibits the growth of most Enterobacteriaceae in concentrations below 2 mg/ml, and of Pseudomonas aeruginosa below 16 mg/ml. It shows a widespread, distribution achieving effective therapeutic concentration there, where infections are seen most frequently. The half-life is from 1.6 to 2.0 hours. It can be administered to patients every 8 and 12 hours in single parenteral doses of 0.5, 1.0, and 2.0 g. Aztreonam is a non-toxic antibiotic, a weak hapten with slight allergenicity. It has found therapeutic use together with the antibiotics directed against aerobic and anaerobic bacterial Gram-positive flora, and it is used in the therapy directed against infections with Gram-negative aerobes. It is an effective antibiotic in nosocomial infections, in oncological patients with neutropenia, and in elderly patients.
Szymkowiak
J
J
I Oddziału Chorób Wewnetrznych Górniczego Centrum Medycznego, Katowicach.
Fojt
E
E
D000368:Aged; D001398:Aztreonam / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D009369:Neoplasms / Q000150:complications; D009503:Neutropenia / Q000188:drug therapy / Q000209:etiology; D015163:Superinfection / Q000188:drug therapy
D001398:Aztreonam
Aztreonam--nowy antybiotyk w leczeniu zakazeń wywoływanych przez gram-ujemne bakterie tlenowe.